Precipio, Inc. income statement
In fiscal 2025, Precipio, Inc. reported revenue of $53.5m, up 28.0% on the year before, operating income of −$1.2m (a -2.2% margin) and net income of −$363,000, or −$0.23 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22 | 20 | 32 | 31 | 28 | 1 | 2 | 2 | 2 | 3 | 8 | 16 | 9 | 20 | 15 | 42 | 53 | 61 |
| Cost of revenue | 10 | 10 | 14 | 18 | 17 | 2 | 2 | 1 | 1 | 3 | 3 | 5 | 6 | 7 | 9 | 11 | 13 | 15 |
| Gross profit | 12 | 10 | 18 | 13 | 11 | −1 | −0 | 1 | 0 | 0 | 0 | 1 | 2 | 3 | 6 | 8 | 11 | 12 |
| Research and development | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | — |
| Selling, general and administrative | 10 | 11 | 19 | 20 | 23 | 7 | 7 | 2 | 6 | 9 | 10 | 10 | — | — | — | — | — | — |
| Operating income | −2 | −4 | −3 | −10 | −16 | −11 | −9 | −2 | −16 | −14 | −11 | −9 | −10 | −13 | −8 | −4 | −1 | −2 |
| Income before tax | −2 | −3 | −10 | −8 | −16 | −11 | −10 | −2 | −21 | −16 | −13 | −11 | −9 | −12 | −6 | −4 | −0 | −1 |
| Income tax | 0 | 0 | 0 | 0 | −0 | 0 | 0 | 0 | 0 | −0 | −0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Net income | −2 | −3 | −10 | −8 | −16 | −14 | −33 | −2 | −21 | −16 | −13 | −14 | −9 | −12 | −6 | −4 | −0 | −1 |
| Diluted EPS | −$0.00 | −$0.10 | −$4.37 | −$2.58 | −$0.19 | −$0.17 | −$0.23 | −$15.73 | −$11.93 | −$23.03 | −$0.78 | −$17.00 | −$0.40 | −$10.73 | −$4.51 | −$2.93 | −$0.23 | −$0.71 |
| Diluted shares (average) | — | 30m | 2m | 3m | 4m | 4m | 7m | 260m | 3m | — | — | — | 1m | 1m | 1m | 1m | 2m | 2m |
| EBITDA | −1 | −3 | −1 | −7 | −13 | −10 | −8 | −2 | −15 | −13 | −10 | −8 | −8 | −12 | −6 | −3 | 0 | −0 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 12 | 11 | 12 | 15 | 15 | 15 | 15 |
| Cost of revenue | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Gross profit | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 3 |
| Operating income | −1 | −0 | −1 | −1 | −0 | 1 | −1 | −1 |
| Income before tax | −1 | −0 | −1 | 0 | −0 | 1 | −1 | −0 |
| Net income | −1 | −0 | −1 | 0 | −0 | 1 | −1 | −0 |
| Diluted EPS | −$0.42 | −$0.24 | −$0.59 | $0.05 | −$0.05 | $0.34 | −$0.81 | −$0.12 |
| EBITDA | −0 | −0 | −1 | −1 | 0 | 1 | −1 | −0 |
Compare with peers
- 908 Devices Inc. income statement
- Champions Oncology, Inc. income statement
- Personalis, Inc. income statement
- Exagen Inc. income statement
- Burning Rock Biotech Ltd income statement
Head to head: MASS vs PRPOCSBR vs PRPOPRPO vs PSNL
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies